Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery  by Parolari, Alessandro et al.
Parolari et al Cardiopulmonary Support and PhysiologyIncreased prothrombotic state lasting as long as one month
after on-pump and off-pump coronary surgery
Alessandro Parolari, MD, PhD,a Luciana Mussoni, PhD,c Marta Frigerio, PhD,a Moreno Naliato, MD,a
Francesco Alamanni, MD,a Andrea Galanti, MD,a Giuseppe Fiore, MD,a Fabrizio Veglia, PhD,b Elena Tremoli, PhD,a,cPaolo Biglioli, MD,a and Marina Camera, Biol Sci, PhDa,c
CS
PFrom the Department of Cardiac Surgerya
and the Biostatistics Unit,b Centro Cardio-
logico Monzino IRCCS, and the Depart-
ment of Pharmacological Sciences,c Uni-
versity of Milan, Milan, Italy.
Supported by the Italian Ministry of Health
(RF 2002 convenzione No. 191).
Received for publication July 12, 2004; re-
visions received Oct 27, 2004; accepted for
publication Nov 2, 2004.
Address for reprints: Alessandro Parolari,
MD, PhD, Department of Cardiac Surgery,
University of Milan, Centro Cardiologico
Fondazione Monzino IRCCS, Via Parea, 4,
20138, Milan, Italy (E-mail: alessandro.
parolari@cardiologicomonzino.it).
J Thorac Cardiovasc Surg 2005;130:303-8
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.002Objective: This study investigated whether the activation of coagulation, fibrinolysis,
and endothelium occurring during the first postoperative month after on-pump coronary
artery bypass surgery differs from that after off-pump coronary artery bypass grafting.
Methods: Thirty-five patients candidates to coronary surgery were randomized to
undergo on-pump (n  18) or off-pump (n  17) coronary artery bypass grafting.
Blood samples were collected before the intervention and to 1 month after surgery.
Results: Prothrombin fragment F1.2, thrombin-antithrombin complex, and D-dimer
increased after surgery and were persistently higher than preoperative values as late
as 30 postoperative days in both on- and off-pump groups; higher levels of these
variables were detected after on-pump surgery relative to off-pump surgery only at
the time point after termination of cardiopulmonary bypass (fragment F1.2 and
thrombin-antithrombin complex) or from bypass end to 8 postoperative days (D-
dimer). Fibrinogen levels decreased after surgery and then increased in parallel in
both groups to 8 days after surgery. The von Willebrand factor level increased
postoperatively in both groups and returned to baseline 30 days after surgery; it was
higher after on-pump surgery from bypass end to 8 postoperative days. Soluble
vascular cell adhesion molecule 1 was increased significantly from baseline in both
groups 30 days after surgery, with no difference between groups.
Conclusion: Patients undergoing off-pump surgery showed protection against acti-
vation of coagulation and fibrinolysis and against endothelial injury only during the
intraoperative period; this was followed by the development of a prothrombotic
pattern comparable to that of patients undergoing on-pump surgery lasting at least
as late as 30 days after surgery.
Studies, mainly performed in patients undergoing coronary artery bypassgrafting (CABG), have shown that cardiopulmonary bypass (CPB) use isassociated with activation of several metabolic pathways and cellular com-
ponents leading to a systemic inflammatory response.1 This response has mainly
been documented to occur in the early hours after surgery, but some studies have
shown a marked activation of the hemostatic, thrombotic, and inflammatory systems
to persist for several weeks after coronary surgery.2-5
During the past decade, several technical advances have allowed the reintroduction
into clinical practice of CABG performed on a beating heart without CPB (OPCAB).
OPCAB has been proposed as a surgical strategy that by avoiding CPB would exten-
sively reduce postoperative inflammatory response.6 It is therefore expected that patients
undergoing OPCAB would experience fewer postoperative adverse events.
The clinical advantage of OPCAB versus standard on-pump CABG is, however,
still debated.7,8 It is also unclear whether CPB is the main cause of the postoperative
inflammatory and procoagulant responses that occur after cardiac surgery; recently,
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CPB, may cause activation of inflammatory and coagula-
tion-fibrinolytic pathways.9
We therefore investigated whether activation of coagu-
lation and fibrinolysis differed between patients undergoing
OPCAB and CABG at the end of surgery. Because graft
occlusion mainly occurs during the first month after the
surgical intervention, the same thrombotic variables were
also assessed to 1 month after surgery.
Patients and Methods
Patients
Thirty-five patients were consecutively enrolled among those can-
didates to elective surgical myocardial revascularization according
to the American Heart Association and American College of
Cardiology guidelines10 and were randomly assigned to undergo
OPCAB (n 17) or CABG (n 18). In all cases, the preoperative
ejection fraction was greater than 30%, and the left ventricular
end-diastolic pressure was below 20 mm Hg. Preoperative exclu-
sion criteria were age older than 80 years, renal or liver disease,
and intake of drugs affecting platelet function or coagulation or
fibrinolysis within 10 days before surgery. Intraoperative and
postoperative exclusion criteria were excessive (1000 mL/d)
postoperative bleeding or reexploration for bleeding, perioperative
TABLE 1. Clinical variables in the study population
Variable
Age (y, mean  SEM)
Male sex (No.)
Previous myocardial infarction (No.)
Type 1 diabetes (No.)
Type 2 diabetes (No.)
Chronic obstructive pulmonary disease (No.)
Hypertension (No.)
Echocardiographic ejection fraction (%, mean  SEM)
Total cholesterol (mg/dL, mean  SEM)
Low-density lipoprotein cholesterol (mg/dL mean  SEM)
High-density lipoprotein cholesterol (mg/dL, mean  SEM)
Plasma triglycerides (mg/dL, mean  SEM)
Preoperative hematocrit (%, mean  SEM)
Diseased coronary vessels (mean  SEM)
Distal anastomoses (mean  SEM)
Distal left internal thoracic artery anastomoses (mean  SEM)
Distal saphenous vein anastomoses (mean  SEM)
Distal radial artery anastomoses (mean  SEM)
CPB time (min, mean  SEM)
Crossclamp time (min, mean  SEM)
2-h bleeding (mL, mean  SEM)
24-h bleeding (mL, mean  SEM)
Total bleeding (mL, mean  SEM)
Ventilation time (h, mean  SEM)
Transfused patients (No.)
Transfused blood (U, mean  SEM)myocardial infarction, stroke, and renal failure requiring dialysis.
304 The Journal of Thoracic and Cardiovascular Surgery ● AuguAll patients gave informed consent to participate in this study,
which was approved by the Ethical Committee of Centro Cardio-
logico Monzino I.R.C.C.S. All patient care has been managed by
the same surgical and anesthesiologic team.
Anesthesia
Patient care management during and after surgery was the same for
both groups of patients. All patients continued their cardiac med-
ications until surgery. Anesthetic premedication was atropine (0.5
mg) and morphine sulfate (0.1 mg/kg) given intramuscularly 1
hour before surgery.
Anesthesia was then induced by the administration of sodium
thiopental (4-5 mg/kg), fentanyl (100 g), succinylcholine (INN:
suxamethonium, 1 mg/kg), and pancuronium bromide (0.1 mg/kg).
After the induction of anesthesia, all patients underwent orotra-
cheal intubation. Cefuroxime (2 g) was given intravenously for
infection prophylaxis. A continuous infusion of propofol was
started after anesthesia induction (3-4 mg/[kg · h]), and boluses of
sufentanil (25 g for a maximum total dose of 0.3 mg) and
pancuronium bromide (2 mg) were given when necessary.
After internal thoracic artery takedown, systemic hepariniza-
tion (300 IU/kg bovine lung heparin) was administered, and acti-
vated clotting time was kept to at least 440 seconds with additional
heparin in both groups. On completion of distal and proximal
coronary anastomoses, heparin was antagonized with protamine
CABG (n  18) OPCAB (n  15) P value
62 2.3 62  2.4 .71
8 (44%) 8 (53%) .99
7 (50%) 7 (64%) .61
1 (6%) 0 (0%) .99
4 (22%) 0 (0%) .11
5 (28%) 4 (27%) .99
11 (61%) 10 (67%) .97
59% 2.7% 56% 2.2% .33
204 11 226  14 .18
137 11 145  13 .63
43 3.1 46  3.1 .45
158 36 196  43 .50
42% 0.6% 44% 1.2% .26
3 0 2.7  0.15 .34
3.1 0.18 2.9  0.26 .46
1.1 0.05 1.3  0.13 .18
1.6 0.20 1.1  0.22 .15
0.4 0.15 0.4  0.13 .96
119 6.3 — —
81 4.6 — —
154 21 141  15 .95
628 58 573  36 .49
701 66 615  36 .37
5.4 0.51 5.0  0.50 .56
3/18 (17%) 1/15 (6.7%) .61
0.6 0.35 0.3  0.27 .34sulfate at a 1:1 ratio (3 mg/kg) in both groups.
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PCABG Surgery
A nonpulsatile roller pump, hollow-fiber oxygenator with inte-
grated heat exchanger, arterial filter, open cardiotomy reservoir,
and polyvinyl tubing system was used in all cases. Each operation
was performed with tepid hypothermia (32°C-34°C) and hemodi-
lution. Blood flow during CPB was maintained at 2.4 L/(min · m2),
and hematocrit was kept at 18% to 25%. Myocardial protection
was achieved by the administration of cool (4°C) multidose (every
15-20 minutes) blood cardioplegia (Buckberg solution) infused
through the aortic root and the coronary sinus.
OPCAB Surgery
All OPCAB procedures were performed through midline sternotomy.
Mechanical stability of the coronary arteriotomy area was achieved
with the Octopus III system (Medtronic, Inc, Minneapolis, Minn), and
a soft plastic coronary flow-shunt was always introduced into the
coronary arteriotomy to maintain some degree of distal flow, to reduce
myocardial ischemia, and to improve visualization of the anastomosis
area. Coronary artery exposure was achieved with stay sutures applied
on the left lateral side of pericardium or with deep pericardial stay
sutures placed above the entry of the left lower pulmonary vein and
laterally to the entry of the inferior vena cava.
Follow-up
All patients were hospitalized until postoperative day 8. Then all
patients underwent a follow-up visit (physical examination, elec-
trocardiogram, and blood collection) at postoperative day 30.
Blood Sampling
Blood collection was performed from the antecubital vein through
TABLE 2. Measured plasma constituents with time
Variable Baseline Protamine 4 d
TAT (ng/mL, mean  SEM)
CABG 3.1 0.39 92.9 9.52*† 19.6 3.68* 1
OPCAB 2.5 0.43 9.1  1.09* 8.2 1.45*
F1.2 (nmol/L, mean  SEM)
CABG 1.38 0.11 4.80 0.37*† 3.96 0.36* 3
OPCAB 1.20 0.12 1.55 0.15 2.64 0.22* 2
Fibrinogen (mg/dL, mean  SEM)
CABG 429 30.3 307 23.7* 878 33.0*
OPCAB 393 16.9 299 18.1* 844 43.1*
XDP (ng/Ml, mean  SEM)
CABG 60 7.0 1250 141.7*† 682 105.6*§ 1
OPCAB 54 8.2 71  8.1 314  51.0*
vWF (U/mL, mean  SEM)
CABG 25 2.8 34  2.3*† 56 3.4*†
OPCAB 22 2.7 21  2.5 44  3.2*
sVCAM (ng/mL, mean  SEM)
CABG 381 21.8 373 19.5 349 30.0
OPCAB 402 27.0 330 22.0 352 21.6
*Significant difference (P  .01, repeated measures ANCOVA) within eac
measures ANCOVA) between CABG and OPCAB groups. ‡Significant diffe
with baseline. §Significant difference (P  .05, repeated measures ANCOa 19-gauge needle in plastic tubes containing 0.13-mol/L sodium
The Journal of Thoracicitrate (1/10 volume/volume) at baseline (the day before surgery),
5 minutes after protamine administration, at stable hemodynamic
conditions, and at 4, 8, and 30 days after surgical intervention.
Plasma was prepared by centrifugation at 1500g for 20 minutes at
4°C within 30 minutes from venipuncture, divided into aliquots,
and frozen at 80°C until assay.
Fibrinogen levels were measured according to Clauss11 (Fibrin-
ogen-C; Instrumentational Laboratory, Milan, Italy) with a coag-
ulometer (ACL 300; Instrumentational Laboratory). Thrombin-
antithrombin complex (TAT), D-dimer (XDP), prothrombin
fragment F1.2 (F1.2), von Willebrand factor (vWF), and soluble
vascular cell adhesion molecule 1 (sVCAM) levels were deter-
mined by enzyme-linked immunosorbent assay with commercially
available kits, according to manufacturers’ recommendations (En-
zygnost TAT Dade Behring; Dimertest GOLD EIA Kit, AGEN
Biomedical Limited; Enzygnost F1.2 Dade Behring; von Wille-
brand Factor ELISA Kit, Gradipore; Human Soluble VCAM-1
Immunoassay, R&D Systems, Inc, Minneapolis, Minn). All data
were normalized for hematocrit values.
Statistical Analysis
Continuous variables are presented as mean  SEM; categorical
variables are presented as percentages. Group differences in clin-
ical variables between CABG and OPCAB were assessed with
Mann-Whitney, 2, or Fisher exact tests as indicated. General
linear model analysis of covariance (ANCOVA) models were used
for statistical analysis of time, group (CABG vs OPCAB), and
interaction (time*group) effects in coagulation, fibrinolytic, and
endothelial activation variables. When time, group, or interaction
8 d 30 d
Main effects ANCOVA
Time Treatment Interaction
.0001 .0002 .0001
4.02* 11.6 3.34‡
0.79* 4.1 0.94‡
.0001 .0043 .0001
0.22* 1.85 0.16‡
0.23* 1.64 0.16*
.0001 .71 .69
26.3* 429 17.5
41.8* 385 14.2
.0419 .0001 .0001
145.4*† 217 31.2*
60.6* 118 22.1‡
.0001 .0001 .33
3.9*† 25 2.5
3.4* 23  3.7
.0439 .18 .23
42.6 550 34.8*
18.1 494 36.3*
up as compared with baseline. †Significant difference (P  .01, repeated
(P  .05, repeated measures ANCOVA) within each group as compared
etween CABG and OPCAB groups.8.1
7.9
.44
.63
788
771
247
570
53
37
469
382
h gro
renceeffects were significant (P  .05), repeated measures analysis of
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icant point-by-point differences.
Results
Thirty-three patients of the original 35 completed the study.
Two patients in the OPCAB group were excluded: 1 be-
cause of excessive bleeding requiring reexploration and 1
because of refusal to participate in the study after random
assignment. No significant differences in clinical variables
were detected between patients randomly assigned to OP-
CAB versus CABG (Table 1). Red blood cells were trans-
fused in 3 patients in the CABG group and 1 in the OPCAB
group, whereas no plasma, platelet, or cryoprecipitate trans-
fusions were needed (Table 1). Also, there were no differ-
ences at baseline between groups in coagulation, fibrino-
lytic, and endothelial activation variables (Table 2).
Coagulation and Fibrinolysis Variables
Persistent postoperative increases in plasma levels of TAT and
F1.2 were observed in both groups relative to baseline; these
persisted at 30 days (Figure 1, A and B, and Table 2). In the
OPCAB group, the increase in TAT levels occurred earlier
Figure 1. Plasma TAT (A), F1.2 (B), fibrinogen (C), and
error bars indicate SEM. Empty circles indicate patients
assigned to OPCAB (n  15). Note that y-axis is logari
(P < .01 by repeated measures ANCOVA) within eac
difference (P < .01 by repeated measures ANCOVA) be
significant difference (P < .05 by repeated measures A
indicates significant difference (P < .05 by repeated mthan that of F1.2, whereas the two variables simultaneously
306 The Journal of Thoracic and Cardiovascular Surgery ● Auguincreased in patients undergoing CABG. Point-by-point anal-
ysis showed significant differences between OPCAB and
CABG only after protamine, with F1.2 and TAT levels higher
in the CABG group. Interestingly, a tendency toward an in-
crease in plasma levels of tissue factor was found at 4 days
after surgery in both groups (data not shown).
Fibrinogen significantly decreased in both OPCAB and
CABG groups (Figure 1, C, and Table 2) after protamine
but markedly increased at 4 and 8 postoperative days, reach-
ing preoperative levels 30 days after surgery with no dif-
ference between the two groups.
After surgery, XDP significantly and persistently (to 30
days) increased in both groups, with a delay in the OPCAB
group (at 4 days after surgery) relative to the CABG group
(Figure 1, D, and Table 2). Point-by-point analysis showed that
the levels of this marker were higher after CABG than after
OPCAB starting from the protamine time point to 8 days after
surgery.
Plasma Markers of Endothelial Injury
The behavior of endothelial injury differed from that of
(D) at each time interval. Data points represent mean;
gned to CABG (n 18); filled squares indicate patients
c in A and D. Asterisk indicates significant difference
up relative to baseline; dagger indicates significant
en CABG and OPCAB groups; double dagger indicates
VA) within each group relative to baseline; dollar sign
ures ANCOVA) between CABG and OPCAB groups.XDP
assi
thmi
h gro
twe
NCO
eascoagulation markers. The vWF level increased after surgery
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Pto 8 postoperative days in both groups but had returned to
baseline levels at 30 days, with levels significantly higher in
the CABG group (Figure 2, A, and Table 2). Finally, in both
groups there was a significant effect of time (P .0439) for
sVCAM, with a significant increase from baseline at 30
days after surgery, whereas no group effect was observed
(Figure 2, B, and Table 2).
Discussion
This study shows that in patients undergoing OPCAB, a
persistent activation of coagulation and of fibrinolytic path-
ways as well as of endothelium occurs and lasts as late as 30
days after surgery. Interestingly, in OPCAB these events are
delayed relative to CABG; in fact, after protamine admin-
istration the levels of F1.2 and XDP in the OPCAB group
were comparable to those at baseline. Likewise, plasma
vWF levels in the OPCAB group paralleled those of blood
coagulation to 8 days after surgery, which suggests a de-
layed endothelial perturbation resolving within the 30 days
of follow-up. On the other hand, sVCAM is unaffected in
the first week after surgery, whereas its levels in plasma
significantly increase 30 days after surgery. A member of
the immunoglobulin family that supports the stable attach-
ment of monocytes to arterial endothelium, sVCAM is an
endothelial marker reflecting the occurrence of atheroscle-
rosis.12 It has been proposed to have a pathogenetic role not
only in early atherogenesis but also in the progression of
advanced atherosclerotic plaques13; the increase in sVCAM
observed at the latest time point in both groups suggests that
activation of this marker occurs irrespective of the surgical
strategy.
Taken together, these data suggest that the avoidance of
extracorporeal circulation protects from the early appear-
ance of a prothrombotic state. However, it does not prevent
the increases in prothrombotic and endothelial injury mark-
ers that occur during the follow-up.
Previous studies in patients undergoing CABG have
shown a marked activation of the coagulation-fibrinolytic
system that lasted several weeks, probably accounting for
the increased thrombotic complications that frequently oc-
cur during the postoperative period.2-5 Indeed, the early
period after coronary surgery is characterized by the highest
rates of myocardial infarction, cerebrovascular accident,
and coronary bypass graft occlusion, all occurring within
the early months after surgery.14 The information about the
behavior of hemostatic and endothelial activation variables
after OPCAB is still limited and is related only to the very
early hours after surgery. Indeed, early after surgery a less
marked reduction in platelet counts, higher plasminogen,
and lower XDP levels relative to CABG were observed, but
no difference between groups was detectable 24 hours lat-
er.15 Also, no significant differences in early (to 8 or 24
hours) postoperative levels of endothelial adhesion mole-
The Journal of Thoracicules, such as intracellular adhesion molecule 1 and P-
selectin, or of endothelial cell activation markers have been
reported.6,16
The analysis of the different activation patterns as seen
after CABG and OPCAB allows us to distinguish two
discrete phases: an early phase, occurring only after CABG,
characterized by a sharp activation of coagulation and fibri-
nolysis, which may be ascribable to the use of extracorpo-
real circulation; and a later phase, occurring in patients
undergoing either CABG or OPCAB, probably consequent
to an inflammatory reaction induced by general surgical
trauma. It has been hypothesized that OPCAB may result in
Figure 2. Plasma vWF (A) and sVCAM (B) at each time interval.
Data points represent mean; error bars indicate SEM. Empty
circles indicate patients assigned to CABG (n  18); filled
squares indicate patients assigned to OPCAB (n  15). Asterisk
indicates significant difference (P < .01 by repeated measures
ANCOVA) within each group relative to baseline; dagger indi-
cates significant difference (P < .01 by repeated measures
ANCOVA) between CABG and OPCAB groups.greater risk of a prothrombotic state than CABG because of
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tion factor consumption.17 In support of this hypothesis is
the observation of early reduced patency rates of bypass
grafts with this type of surgical approach.18 Our data indi-
cate that the overall pattern of coagulation activation after
OPCAB is significantly lower than that after CABG during
the surgical intervention but similar to that after CABG
during the follow-up.
Recently, it has been reported that platelet inhibition by
aspirin is compromised within several days after CABG,
probably because of an impaired interaction between aspirin
and platelet cyclooxygenase.19 In this study, the behavior of
platelets was not investigated, leaving open the question of
whether a greater activation occurs during OPCAB or
CABG.
Evidence concerning definitive clinical advantages of
either technique of surgical myocardial revascularization is
currently lacking, and the differences between OPCAB and
CABG in terms of early clinical outcomes are so limited
that very large randomized studies would be needed to
ascertain the superiority of either technique.20 The modest
activation of coagulation and fibrinolysis in OPCAB during
surgery relative to CABG confirms and extends previous
findings that document the protective effect of this surgical
strategy against pro-oxidant, proinflammatory, and pro-
thrombotic activation. During the midterm follow-up, what-
ever surgical strategy is adopted, a significant prothrom-
botic activation occurs and persists for several days or even
weeks after surgery. This is accompanied by endothelial
injury, as shown by postoperative increases in both groups
of vWF, a glycoprotein synthesized by the endothelium and
stored in Weibel-Palades bodies that is a selective marker of
endothelial injury inflammatory vascular disease,21 and by a
delayed proatherosclerotic atherogenic burden, as shown by
the delayed increase of sVCAM levels 30 days after sur-
gery. The data here reported, together with the evidence of
platelet resistance to aspirin in patients undergoing CABG,
raise the issue of the need of reevaluating antithrombotic
treatment in both OPCAB and CABG.
The excellent technical assistance of Franco Moro is gratefully
acknowledged.
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